Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04158362
Title Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (AMBRE)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors UNICANCER
Indications

Her2-receptor negative breast cancer

Therapies

Capecitabine

Abemaciclib + Fulvestrant

Abemaciclib + Letrozole

Paclitaxel

Abemaciclib + Anastrozole

Age Groups: adult | senior
Covered Countries


No variant requirements are available.